Retroperitoneal Single Port vs Transperitoneal Multiport Robot Assisted Partial Nephrectomy (RAPN) in Patients with Highly Hostile Abdomens, a tertiary referral center comparative analysis

Retroperitoneal Single Port vs Transperitoneal Multiport Robot Assisted Partial Nephrectomy (RAPN) in Patients with Highly Hostile Abdomens, a tertiary referral center comparative analysis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Retroperitoneal Single Port vs Transperitoneal Multiport Robot Assisted Partial Nephrectomy (RAPN) in Patients with Highly Hostile Abdomens, a tertiary referral center comparative analysis Luca Lambertini, Matteo Pacini, Ruben Sauer Calvo, Juan Ramon Torres Anguiano, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4829943/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Purpose To explore perioperative and functional outcomes in a cohort of patients with highly hostile abdomens treated with retroperitoneal single port vs transperitoneal multiport robot assisted partial nephrectomy. Materials and Methods Clinical and surgical data of all consecutive patients treated with Transperitoneal Multiport and Retroperitoneal Single-Port Robot Assisted Partial Nephrectomy between March 2019 and January 2024 were prospectively collected and retrospectively analyzed. The presence of “hostile abdomen” was defined as personal history of at least one major abdominal surgery. Multivariable logistic regression analysis was used to assess independent predictors of Trifecta achievement. Results Overall, clinical and surgical data of 247 consecutive patients were prospectively collected, of these 71 met the inclusions criteria and were retrospectively analyzed. No differences emerged in baseline features. Previous surgery proximity to the site of partial nephrectomy was found comparable among groups (p = 0.21). Retroperitoneal single port group showed a significantly lower operative time (171 vs 235 min, p = 0.02) and estimated blood loss (70 vs 100 cc, p = 0.04) while open conversion was significantly higher (9.3%) in case of multiport treatment (p = 0.001). A significative lower rate of major postoperative complications (7.1 vs 16.3%, p = 0.03) as well as 90-days readmissions (p = 0.04) was found in case of single port retroperitoneal procedures. Adjusting for age, BMI and CCI, retroperitoneal single port approach was confirmed as independent predictor of Trifecta achievement (OR 1.62 CI 1.18–2.35 p = 0.01). Conclusion Single port retroperitoneal approach confirmed valuable perioperative outcomes reducing the major complication rate and minimizing the overall surgical impact on patients as compared to the multiport transperitoneal group. Previous surgery Robotics Nephrectomy Renal cancer Complications Figures Figure 1 Figure 2 Introduction Dealing with hostile abdomens still represents one of the main surgical challenges in minimally invasive surgery[ 1 ]. Particularly, the worldwide spread of minimally invasive Partial Nephrectomy (PN) for localized T1 renal masses and the continuous advancements in robotic surgery, have widened the indications of Robot Assisted Partial Nephrectomy (RAPN) also in patients with personal history of major abdominal surgery[ 2 ]. In this setting, the retroperitoneal (RP) surgical access may overcome the limitations of the transperitoneal (TP) one by reducing the risk of adhesions-related intraoperative and perioperative complications as well as shortening the operative time[ 3 ]. Given the central role of surgeons preference in the approach-selection, a clear trend emerged in favor of the adoption of the TP over the RP approach, also due to the wider working space required by the Multi-Port (MP) systems [ 4 – 5 ]. The recent introduction of da Vinci single-port (SP) robotic platform (Intuitive Surgical, Sunnyvale, CA) may shift this paradigm. Indeed, the high flexibility of surgical instruments and the narrow space required for triangulation allow to bring the kidney surgery back to the retroperitoneal space possibly avoiding the above-mentioned adhesion-related issues[ 6 ]. To date, initial data from both single-center[ 7 – 9 ] and multi-institutional series[ 10 ] assessed the feasibility of SP-RAPN in unselected patients showing promising results. Nevertheless, evaluating its benefits and harms in highly complex patients still represent an unmet need. As such, we sought to compare retroperitoneal single port RAPN vs transperitoneal multiport RAPN in terms of perioperative and functional outcomes in a cohort of patients with highly hostile abdomens. Materials and Methods Study population Surgical data of all consecutive patients treated between March 2019 and January 2024 with RP Single-and TP Multi-Port Robot Assisted Partial Nephrectomy at a single center (UIH, Chicago, Illinois, USA) were prospectively included in a self-maintained database and retrospectively gathered. All patients with localized renal masses amenable to partial nephrectomy were included. Demographic, oncologic and perioperative features were collected by a dedicated clinical software (Epic system®) and assessed. The RENAL nephrometry score [ 11 ] was evaluated for each patient basing on the preoperative cross-sectional imaging. Intraoperative and postoperative complications were graded by the Clavien–Dindo classification system [ 12 ] while significant renal function loss was defined in case of ΔeGFR (difference between eGFR at 6-month follow-up and baseline) > 25%. The Trifecta achievement was defined accordingly with Kaouk et al.[ 13 ] as the presence of negative pathological surgical margins, absence of perioperative complications and warm ischemia time < 25 minutes. Hostile Abdomen The presence of “hostile abdomen” was defined as the personal history of at least one major transperitoneal abdominal surgery (a comprehensive report is provided in Supplementary Table 1). Previous surgery was also compared according to its proximity to the site of the partial nephrectomy in two categories (upper contralateral/lower abdominal quadrant or minimally invasive, upper ipsilateral abdominal quadrant or middle line). Only patients with “hostile abdomen” were included in the analysis. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The present research was performed after local ethical commitment approval IRB 20201428. Basing on surgical approach, patients were stratified in two groups (Retroperitoneal SP-RAPN vs Transperitoneal MP-RAPN). Surgical technique All transperitoneal MP-RAPN cases were performed at our institution by two surgeons with extensive experience using the standard multiport da Vinci Xi system according to the previously described standard technique [ 14 ]. All retroperitoneal SP-RAPN procedures were performed with da Intuitive daVinci SP system® and surgical approach was defined according to the surgeon's preference as previously reported (full flank standard approach vs Low Anterior Access (LAA)[ 6 ]). Statistical analysis The Statistical analyses were conducted following established guidelines [ 16 ]. Descriptive statistics were obtained reporting medians (and interquartile range, IQR) for continuous variables, while frequencies and proportions were used for categorical variables. After testing the normality of variables’ distribution (by the Kolmogorov-Smirnov test), continuous variables were compared by the Mann-Whitney test. We statistically analyzed baseline characteristics and peri- and post-operative outcomes, comparing the TP MP- and the RP SP- RAPN. Multivariable logistic regression analysis was used to test the probability of the Trifecta achievement adjusting for surgical approach, ASA score, CCI and BMI. All statistical analyses were performed using R software (version 4.3.2). Results Overall, clinical and surgical data of 247 consecutive patients treated with RAPN at our institution were prospectively collected and retrospectively analyzed. Of these, 87 (35.2%) were treated with retroperitoneal SP-RAPN while 113 (45.7%) underwent transperitoneal MP-RAPN. The presence of complex abdomen was recorded in 28 (32.2%) and 43 (38.1%) cases in the RP SP-RAPN and TP MP-RAPN, respectively. A detailed description of patient previous abdominal surgery is represented in Supplementary Table 1. In terms of baseline features no significant differences were recorded, median age at surgery was 57 (IQR 44–68) and 58 (IQR 48–65) years while median BMI was 30.12 (IQR 26.1–36.6) and 31.30 (IQR 25.1–38.3) kg/m2 in the RP SP-RAPN and TP MP-RAPN, respectively (p = 0.8, p = 0.18). Previous surgery proximity to the site of partial nephrectomy was found comparable among groups (p = 0.21). Although preoperative hypertension was found higher among the SP group (p = 0.04), no differences emerged in overall patient complexity with a median CCI score of 3 (IQR 2–4) and 3 (IQR 2–5) in the RP SP-RAPN and TP MP-RAPN, respectively (p = 0.7) Table 1 . As regards tumor features, no significant differences were recoded between groups in terms median RENAL Nephrometry Score (8 [IQR 6–9] vs 7 [IQR 5–8] p = 0.2) as well as clinical T stage (p = 0.9) while a slightly higher although not significant rate of posterior tumors was recorded in the SP group (p = 0.06). Considering intraoperative outcomes, RP SP-RAPN showed a significantly lower operative time (171 min [IQR 104–238] vs 235 min [IQR 160–302)], p = 0.02) and estimated blood loss (70 cc [IQR 40–170)] vs 100 cc [IQR 60–200], p = 0.04), Fig. 1 . Open conversion occurred in the 9.3% of patients treated with TP MP-RAPN while no cases were recorded in the RP SP-RAPN group (p = 0.001). In term of hilar clamping no significant differences were found among groups with a slightly higher rate of off-clamp procedures in the MP group (p = 0.07), Table 2 . As regards postoperative outcomes, a significantly lower rate of major postoperative complications was found in the RP SP-RAPN group as compared to the TP MP-RAPN (7.1% vs 16.3%, p = 0.03), as well as a significantly lower rate of 90-days readmission (7.1% vs 14.1%, p = 0.04) Supplementary Table 2. In terms of mid-term surgical and functional outcomes, after a median follow up of 16 months (IQR 6–24) no differences were recorded in terms of significant renal function loss (p = 0.9). Adjusting for age, BMI and CCI, RP SP-RAPN was confirmed as independent predictor of Trifecta achievement (OR 1.62 CI 1.18–2.35 p = 0.01), Supplementary Table 3. Table 1 Comparison of the preoperative characteristics of patients with hostile abdomen treated with transperitoneal multiport or retroperitoneal single port RAPN Characteristic Overall, N = 71 1 Multiport Transperitoneal RAPN, N = 43 1 Single Port Retroperitoneal RAPN, N = 28 1 p-value 2 Age at Surgery, median (IQR) 58 (48–65) 58 (48–65) 57 (44–68) 0.8 Gender (male), n (%) 47 (66.2) 28 (65.1) 19 (67.9) 0.08 BMI (kg/m2), median (IQR) 30.8 (25.6–37.6) 31.3 (25.1–38.3) 30.1 (26.1–36.6) 0.18 Race, n (%) 0.06 White 18 (25.4) 11 (25.6% 7 (25) Black 18 (25.4) 10 (23.3) 8 (28.6) Hispanic 15 (21.1) 9 (20.9) 6 (21.4) Chinese 9 (12.6) 5 (11.6) 4 (14.2) South-Asia 11 (15.5) 8 (18.6) 3 (10.8) CCI, median (IQR) 4 (3–5) 4 (3–5) 4 (3–5) 0.7 ASA, median (IQR) 3 (2–4) 3 (2–4) 3 (2–5) 0.7 Hypertension, n (%) 43 (61%) 22 (51%) 21 (75%) 0.04 Diabetes, n (%) 24 (34%) 14 (33%) 10 (36%) 0.8 Antiplatelet or anticoagulant therapy, n (%) 15 (21%) 9 (20.8%) 6 (21%) > 0.9 Previous surgery location, n (%) Upper contralateral, lower abdominal quadrants or minimally invasive, n(%) 45 (63.4) 28 (65.1) 17 (60.7) 0.6 Upper ipsilateral abdominal quadrant or middle line, n(%) 26 (36.6) 15 (34.9) 11 (39.3) 0.11 Preoperative Hb (g/dL), median (IQR) 12.40 (9.7–15.8) 12.30 (10.1–15.3) 12.80 (9.2–16.7) 0.4 Preoperative serum creatinine (mg/dL), median (IQR) 0.83 (0.71–1.3) 0.71 (0.65–1.1) 0.88 (0.67–1.4) 0.7 Preoperative eGFR (mL/min/1.73m2), median (IQR) 87 (51–90) 84 (49–86) 88 (58–90) 0.4 Clinical tumor size (mm), median (IQR) 2.50 (1.9–3.7) 2.55 (1.7–3.8) 2.50 (1.5–3.6) 0.9 Clinical T stage, n (%) 0.9 cT1a 61 (85.9) 36 (83.8) 25 (89.2) cT1b 10 (14.1) 7 (16.2) 3 (10.8) Renal Nephrometry score, median (IQR) 7 (5–9) 7 (5–8) 8 (6–9) 0.2 Posterior lesions, n(%) 26 (36.6) 15 (34.9) 11 (39.4) 0.06 1 Median (IQR); n / N (%) 2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test Table 2 Perioperative and pathological outcomes of patients with hostile abdomen treated with transperitoneal multiport or retroperitoneal single port RAPN Characteristic Overall, N = 71 1 Multiport Transperitoneal RAPN, N = 43 1 Single Port Retroperitoneal RAPN, N = 28 1 p-value 2 Operative time (min), median (IQR) 197 (120–280) 235 (160–302) 171 (104–238) 0.019 EBL (cc), median (IQR) 80 (50–130) 100 (60–200) 70 (40–170) 0.04 Clampless procedures, n (%) 8 (11.3) 5 (11.6) 3 (10.7) 0.11 Ischemia Time (min), median (IQR) 18 (14–22) 18 (14–21) 19 (16–23) 0.09 Open conversion, n (%) 4 (5.6%) 4 (9.3%) 0 (0%) 0.001 Transfusion rate, n(%) 7 (9.8) 5 (11.6) 2 (7.1) 0.08 Hb level at discharge (g/dL), median (IQR) 10.7 (9.7–15.8) 10.4 (9.2–13.1) 11.1 (9.9–14.1) 0.8 Serum creatinine level at discharge (mg/dL), median (IQR) 1.12 (0.71–1.3) 1.10 (0.87–1.32) 1.18 (0.91–1.43) 0.7 eGFR level at discharge (mL/min/1.73m2), median (IQR) 69 (51–90) 71 (46–84) 67(43–82) 0.4 Length of Hospital stay (LOS), median (IQR) 2 (0–3) 3 (2–4) 0 (0–1) 0.001 Opioid use on 0 or 1 PO Day, n (%) 53 (74.0) 33 (76.7) 10 (35.7) 0.001 Narcotic use one week after surgery, n (%) 12 (16.4) 9 (20.9) 3 (10.7) 0.03 Early postoperative complications CD ≥ 3a, n (%) 9 (12.7%) 7 (16.3%) 2 (7.1%) 0.03 90-days readmission rate, n (%) 16 (23) 6 (14.1) 2 (7.1) 0.04 Positive Surgical Margin, n (%) 6 (9.9) 4 (13.9) 2 (7.1) 0.2 Pathological T stage, n (%) 63 (88.7) 40 (93.0) 23 (82.1) 0.9 pT1a 52 (82.5) 33 (75.0) 19 (82.6) pT1b 11 (15.5) 7 (17.5) 4 (17.4) Significant renal function loss at last follow up 3 , n(%) 32 (45) 19 (44) 13 (46) 0.9 Follow-up, median (IQR) 18 (12–24) 20 (14–26) 16 (12–20) 0.06 1 Median (IQR); n / N (%) 2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test Discussion During the last decades, minimally invasive nephron sparing surgery further widened its broadens confirming valuable outcomes in managing more complex patient and tumors settings [ 17 – 19 ]. Nevertheless, the presence of intraperitoneal adhesions due to previous major abdominal surgery still represent a non-negligible surgical challenge possibly jeopardizing perioperative safety and prolonging the operative time [ 4 ]. Notwithstanding the theoretical advantages provided by the RP approach in these patients, the confined space of work and the less familiar anatomical landmarks still burden on its adoption across the urological community [ 20 ]. This factor is also driven by the inherent limitations of multiport robotic systems that have led to a progressive shift of kidney surgery towards the transperitoneal approach [ 21 ]. In this scenario, several preliminary series evaluating SP-RAPN outlined a trend reversal with a growing body of surgeons performing RP approach with both full flank and supine patient positioning [ 7 – 10 ]. Nevertheless, the potential benefits of RP SP-RAPN in the complex abdomen patient-setting are still undetermined. To the best of our knowledge, this represents the first series focused on patients with hostile abdomens comparing perioperative and functional outcomes of transperitoneal MP- vs retroperitoneal SP- RAPN. First key finding of our research is that RP SP-RAPN significantly reduced the rates of perioperative complications as compared to the transperitoneal MP group, thus increasing the surgical safety in patients with hostile abdomens. This result might be explained by the reduced tissue dissection and the avoidance of adhesiolysis that is usually performed laparoscopically in the first steps of MP procedures, often representing in this setting a technically demanding surgery [ 22 ]. Consistently to our results, a large multi-institutional matched series assessing both robot-assisted and laparoscopic TP vs RP PN outlined a significant higher major-complications rate in case of transperitoneal procedures [ 23 ]. Conversely, a recent comparative series assessing trans- versus retroperitoneal MP RAPN pointed out no differences in terms of perioperative complications across study cohorts [ 21 ]. To date, previous surgery was reported in few than the 20% of patients and no data regarding the kind of surgery were provided, possibly lowering the statistical burden of extended adhesiolysis in the perioperative outcome assessment. Although a recent meta-analysis by Carbonara et. al[ 4 ] found a higher overall complications rate considering both matched and unmatched series in the TP vs RP approach, no differences were found in terms of CD ≥ 3a complications. Beyond first appearance, our findings are possibly in line with these reports non-focused on complex abdomens. Indeed, our highly surgically complex study population might have enhanced the pre-existing differences between approaches, thus bringing to the surface different safety profiles when it deals with previous major surgery. In this light, in our series open conversion rate was significantly higher in the transperitoneal group occurring in up to the 9% of cases while no conversions were recorded in the RP SP group, confirming its higher feasibility in these patients. Secondly, as compared to the transperitoneal group RP SP-RAPN significantly reduced EBL, operative time and LOS also improving pain management and opioid administration. The convergence of these factors makes a strong argument in favor of both SP and RP adoption in minimizing the surgical impact on complex patients. From a perioperative standpoint, the advantages of the retroperitoneal approach have been widely discussed across current literature with several series identifying the surgeon preference as the main limiting factor in its adoption [ 4 , 21 , 24 ]. In this scenario, the introduction of SP surgical system may play a pivotal role making easier and more feasible dealing with the retroperitoneal space also in challenging cases [ 6 , 25 ]. On top of that, given the median BMI up to 30 kg/m2 of our study population, the presence of abundant perinephric fat did not affect the feasibility of the SP RP approach, with reported perioperative outcomes consistent with current literature [ 19 , 26 ]. Third, assessing the Trifecta achievement accordingly with Kaouk et al.[ 13 ] as a surrogate of surgical and oncological safety, the RP SP group showed significative higher values as compared to the MP procedures (Fig. 2 ). Acknowledging the burden of perioperative complications in this statistical significance, is interesting to notice that PSM rate was comparable among groups even in case of anterior lesions. With the advent of minimally invasive surgery, the retroperitoneal approach was always preferred by surgeons for managing posterior renal masses, while anterior lesions were typically managed transperitoneally[ 27 ]. Conversely, in our study a relatively high value of anterior lesion was found in the RP group. This factor is possibly driven by the high rate of SP-RAPN performed with supine LAA (76%), thus confirming its versatility and surgical benefits across a wide variety of procedures on the upper urinary tract and regardless to the tumor location [ 28 ]. This study is not devoid from limitations. Firstly, the retrospective nature of the analysis in conjunction with the single-center and multiple-surgeon setting may have introduced non-negligible biases. Secondly, the reproducibility of the reported results may have been reduced by the small sample size. To date, to the best of our knowledge this constitutes the larger series focused on perioperative outcomes of SP PN in patients with complex abdomens through current literature. Finally, the density of peritoneal adhesions was not determined intraoperatively due to the retrospective study design. Nevertheless, only patients with high risk of adhesions formation due to previous major procedures were included, possibly reducing the aforementioned flaws [ 29 ], [ 30 ]. Concluding, further muti-center series with longer follow up and larger sample size are still warranted to assess our preliminary outcomes. Conclusions In a cohort of patients with highly hostile abdomens treated with RAPN, single port retroperitoneal approach confirmed valuable perioperative outcomes reducing the perioperative complication rate as compared to the multiport transperitoneal approach. Additionally, in this patient setting retroperitoneal single port access minimized the overall surgical impact in patients by improving EBL, operative time, LOS and pain management. Further multicenter series with longer follow up assessment are still warranted to evaluate our preliminary results. Declarations Acknowledgments None. Funding No funding was received in each step of this research. Conflicts of interest/Competing interests Financial interests: The authors declare they have no financial interests. Non-financial interests: None. Authors contributions: Conceptualization Luca Lambertini, Simone Crivellaro; Data curation Gabriele Bignante, Francesco Lasorsa, Matteo Pacini, Francesca Valastro; Formal analysis; Luca Lambertini, Fabrizio Di Maida, Andrea Mari, Investigation Donato Cannoletta, Greta Pettenuzzo; Methodology Ruben Sauer, Juan Ramon Torres Anguiano; Supervision Alessandro Zucchi; Validation Andrea Minervini; Writing - original draft Luca lambertini; and Writing - review & editing Luca Lambertini, Simone Crivellaro. Data Availability Statement: The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Ethics Committee Approval: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The present research was performed after local ethical commitment approval (University of Illinois in Chicago, 26 th June 2016) IRB 20201428. Consent to participate: Informed consent was obtained from all individual participants included in the study. The authors affirm that human research participants provided informed consent for publication of the collected data. References Petros FG et al (Aug. 2011) Robotic partial nephrectomy in the setting of prior abdominal surgery. BJU Int 108(3):413–419. 10.1111/j.1464-410X.2010.09803.x Zargar H et al (2015) Dec., Robot-assisted laparoscopic partial nephrectomy in patients with previous abdominal surgery: single center experience., Int J Med Robot , vol. 11, no. 4, pp. 389–394, 10.1002/rcs.1633 Arora S et al (Oct. 2018) Retroperitoneal vs Transperitoneal Robot-assisted Partial Nephrectomy: Comparison in a Multi-institutional Setting. Urology 120:131–137. 10.1016/j.urology.2018.06.026 Carbonara U et al (Jun. 2022) Retroperitoneal Robot-assisted Partial Nephrectomy: A Systematic Review and Pooled Analysis of Comparative Outcomes. Eur Urol Open Sci 40:27–37. 10.1016/j.euros.2022.03.015 Fu J, Ye S, Ye H (Dec. 2015) Retroperitoneal Versus Transperitoneal Laparoscopic Partial Nephrectomy: A Systematic Review and Meta-analysis. Chin Med Sci J 30(4):239–244. 10.1016/s1001-9294(16)30007-4 Pellegrino AA, Chen G, Morgantini L, Calvo RS, Crivellaro S (2023) Simplifying Retroperitoneal Robotic Single-port Surgery: Novel Supine Anterior Retroperitoneal Access., Eur Urol , vol. 84, no. 2, pp. 223–228, Aug. 10.1016/j.eururo.2023.05.006 Glaser ZA et al (2022) Jun., Single- versus multi-port robotic partial nephrectomy: a comparative analysis of perioperative outcomes and analgesic requirements., J Robot Surg , vol. 16, no. 3, pp. 695–703, 10.1007/s11701-021-01271-y Harrison R et al (Feb. 2023) Single-port versus multiport partial nephrectomy: a propensity-score-matched comparison of perioperative and short-term outcomes. J Robot Surg 17(1):223–231. 10.1007/s11701-022-01415-8 Licari LC et al (Mar. 2024) Single-port vs multi-port robot-assisted partial nephrectomy: A single center propensity score-matched analysis. Eur J Surg Oncol 50(3):108011. 10.1016/j.ejso.2024.108011 Okhawere KE et al (2022) Dec., A Propensity-Matched Comparison of the Perioperative Outcomes Between Single-Port and Multi-Port Robotic Assisted Partial Nephrectomy: A Report from the Single Port Advanced Research Consortium (SPARC)., J Endourol , vol. 36, no. 12, pp. 1526–1531, 10.1089/end.2022.0115 Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth., J Urol , vol. 182, no. 3, pp. 844–853, Sep. 10.1016/j.juro.2009.05.035 Clavien PA et al (Aug. 2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196. 10.1097/SLA.0b013e3181b13ca2 Khalifeh A et al (Apr. 2013) Comparative outcomes and assessment of trifecta in 500 robotic and laparoscopic partial nephrectomy cases: a single surgeon experience. J Urol 189(4):1236–1242. 10.1016/j.juro.2012.10.021 Larcher A et al (2019) Feb., The Learning Curve for Robot-assisted Partial Nephrectomy: Impact of Surgical Experience on Perioperative Outcomes., Switzerland . 10.1016/j.eururo.2018.08.042 Rohi A, Olofsson MET, Jakobsson JG (2022) Ambulatory anesthesia and discharge: an update around guidelines and trends., Curr Opin Anaesthesiol , vol. 35, no. 6, pp. 691–697, Dec. 10.1097/ACO.0000000000001194 Assel M et al (2019) Mar., Guidelines for Reporting of Statistics for Clinical Research in Urology., Switzerland . 10.1016/j.eururo.2018.12.014 Di Maida F et al (2022) Surgical Management of Synchronous, Bilateral Renal Masses: A 1-decade Referral Center Experience, Eur Urol Focus , no. xxxx, pp. 1–9, 10.1016/j.euf.2022.01.010 Di Maida F et al (2023) Nov., Redo Partial Nephrectomy for Local Recurrence After Previous Nephron-sparing Surgery. Surgical Insights and Oncologic Results from a High-volume Robotic Center., Eur Urol Open Sci , vol. 57, pp. 84–90, 10.1016/j.euros.2023.09.007 Lambertini L et al (Apr. 2024) Minimally invasive transperitoneal partial versus radical nephrectomy in obese patients: perioperative and long-term functional outcomes from a large perspective contemporary series (RECORd2 project). Minerva Urol Nephrol 76(2):185–194. 10.23736/S2724-6051.24.05692-1 Bourgi A, Ayoub E, Merhej S, Souky J, Roupret M, Bruyère F (2023) A comparison of perioperative outcomes of transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a systematic review., J Robot Surg , vol. 17, no. 6, pp. 2563–2574, Dec. 10.1007/s11701-023-01685-w Bertolo R et al (Feb. 2024) Postoperative outcomes of transperitoneal versus retroperitoneal robotic partial nephrectomy: a propensity-score matched comparison focused on patient mobilization, return to bowel function, and pain. J Robot Surg 18(1):96. 10.1007/s11701-024-01860-7 Abaza R, Gerhard RS, Martinez O (May 2020) Feasibility of adopting retroperitoneal robotic partial nephrectomy after extensive transperitoneal experience. World J Urol 38(5):1087–1092. 10.1007/s00345-019-02935-z Porpiglia F et al (2021) Aug., Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (The RECORD 2 Project)., Surg Endosc , vol. 35, no. 8, pp. 4295–4304, 10.1007/s00464-020-07919-4 Porpiglia F et al (2021) Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (The RECORD 2 Project). Surg Endosc 35(8):4295–4304. 10.1007/s00464-020-07919-4 Palacios AR, Morgantini L, Trippel R, Crivellaro S, Abern MR (2022) Comparison of Perioperative Outcomes Between Retroperitoneal Single-Port and Multiport Robot-Assisted Partial Nephrectomies., J Endourol , vol. 36, no. 12, pp. 1545–1550, Dec. 10.1089/end.2022.0346 Malkoc E et al (2017) Feb., Robot-assisted approach improves surgical outcomes in obese patients undergoing partial nephrectomy., BJU Int , vol. 119, no. 2, pp. 283–288, 10.1111/bju.13675 Rich JM et al (2023) Nov., Transperitoneal Versus Retroperitoneal Single-port Robotic-assisted Partial Nephrectomy: An Analysis from the Single Port Advanced Research Consortium., Eur Urol Focus , vol. 9, no. 6, pp. 1059–1064, 10.1016/j.euf.2023.06.004 Razdan S et al (May 2024) Comparison of lateral flank approach and low anterior access for single port (SP) retroperitoneal partial nephrectomy: an analysis from the single port advanced research consortium (SPARC). J Robot Surg 18(1):216. 10.1007/s11701-024-01969-9 Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL (2001) Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg 18(4):260–273. 10.1159/000050149 Ceyhan E et al (2021) Pathology associated with adherent perirenal fat and its clinical effect. Int J Clin Pract 75(10):1–7. 10.1111/ijcp.14518 Additional Declarations No competing interests reported. Supplementary Files SupplementaryTable1.docx SupplementaryTable2.docx SupplementaryTable3.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4829943","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":345384715,"identity":"21bf4884-c309-4058-899e-3461e1b2cbfd","order_by":0,"name":"Luca Lambertini","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA8UlEQVRIiWNgGAWjYBACPgbmBgbGBiCLmYHh8J8KEIO5Aa8WNpB6kBYeoJYDPGdAWhiJ1QLi8baBSMJaGj/d3GGTb8/Oe/CA5LzaaP52oJYfFdvwaWmWzj2TZtnDzJdwwHDb8dwZhxkbGHvO3MbrMOnctsMGPMw8BgcStx3LbQBqYWZsw6ul+Xdu23+IloNzjuXOJ0JLG9CWA2AtBxsbanI3ENQClLXOPZNswHOYx+Aww7EDuRuBWg7i8ws/e/Ph27k77AzY+88Yf2aoqcudd/7wwQc/KnBrAUU6MjgMJg/gVo8J6khRPApGwSgYBSMEAACsMlVtLJSLUQAAAABJRU5ErkJggg==","orcid":"","institution":"University of Illinois at Chicago","correspondingAuthor":true,"prefix":"","firstName":"Luca","middleName":"","lastName":"Lambertini","suffix":""},{"id":345384716,"identity":"2fd9e61a-81c8-4879-b69a-4e5d64af55cd","order_by":1,"name":"Matteo Pacini","email":"","orcid":"","institution":"University of Illinois at Chicago","correspondingAuthor":false,"prefix":"","firstName":"Matteo","middleName":"","lastName":"Pacini","suffix":""},{"id":345384717,"identity":"b547678e-958d-46ea-9a95-ba2704b78784","order_by":2,"name":"Ruben Sauer Calvo","email":"","orcid":"","institution":"University of Illinois at Chicago","correspondingAuthor":false,"prefix":"","firstName":"Ruben","middleName":"Sauer","lastName":"Calvo","suffix":""},{"id":345384718,"identity":"2f28ea05-ab6a-4709-b0e1-53b996ba02c1","order_by":3,"name":"Juan Ramon Torres Anguiano","email":"","orcid":"","institution":"University of Illinois at Chicago","correspondingAuthor":false,"prefix":"","firstName":"Juan","middleName":"Ramon Torres","lastName":"Anguiano","suffix":""},{"id":345384719,"identity":"1ee13c9f-f6f9-4d09-bac5-4aa621e8113a","order_by":4,"name":"Donato Cannoletta","email":"","orcid":"","institution":"University of Illinois at Chicago","correspondingAuthor":false,"prefix":"","firstName":"Donato","middleName":"","lastName":"Cannoletta","suffix":""},{"id":345384720,"identity":"70861ba7-0a63-4485-92de-0915f6c6866e","order_by":5,"name":"Greta Pettenuzzo","email":"","orcid":"","institution":"University of Illinois at Chicago","correspondingAuthor":false,"prefix":"","firstName":"Greta","middleName":"","lastName":"Pettenuzzo","suffix":""},{"id":345384722,"identity":"da1692dc-348d-4829-89f5-e7f93e9fdadb","order_by":6,"name":"Fabrizio Di Maida","email":"","orcid":"","institution":"University of Florence, Careggi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Fabrizio","middleName":"Di","lastName":"Maida","suffix":""},{"id":345384723,"identity":"1f4f4336-9674-4de9-b6c2-6c1a4e8d5a44","order_by":7,"name":"Francesca Valastro","email":"","orcid":"","institution":"University of Florence, Careggi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Francesca","middleName":"","lastName":"Valastro","suffix":""},{"id":345384725,"identity":"c17c96a0-88cc-4173-a24a-d4ee38bded83","order_by":8,"name":"Andrea Mari","email":"","orcid":"","institution":"University of Florence, Careggi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Andrea","middleName":"","lastName":"Mari","suffix":""},{"id":345384726,"identity":"e3f599b4-5503-40a2-b473-5a1cf9a89e9d","order_by":9,"name":"Gabriele Bignante","email":"","orcid":"","institution":"University of Turin, San Luigi Gonzaga Hospital","correspondingAuthor":false,"prefix":"","firstName":"Gabriele","middleName":"","lastName":"Bignante","suffix":""},{"id":345384727,"identity":"78d7fa3a-7c67-4284-8cbb-1773b79aadad","order_by":10,"name":"Francesco Lasorsa","email":"","orcid":"","institution":"University of Bari \"Aldo Moro\"","correspondingAuthor":false,"prefix":"","firstName":"Francesco","middleName":"","lastName":"Lasorsa","suffix":""},{"id":345384728,"identity":"0317da45-52c7-443f-99c0-ed9b74a19972","order_by":11,"name":"Hakan Bahadir Haberal","email":"","orcid":"","institution":"Ankara Ataturk Sanatoryum Training and Research Hospital, University of Health Sciences","correspondingAuthor":false,"prefix":"","firstName":"Hakan","middleName":"Bahadir","lastName":"Haberal","suffix":""},{"id":345384729,"identity":"6bfdcf9b-444d-4f1b-8ec7-b86c8f2a1c9d","order_by":12,"name":"Alessandro Zucchi","email":"","orcid":"","institution":"University of Pisa","correspondingAuthor":false,"prefix":"","firstName":"Alessandro","middleName":"","lastName":"Zucchi","suffix":""},{"id":345384730,"identity":"d6acf12c-ff9b-4a90-b7b3-b2ecad01fcdf","order_by":13,"name":"Andrea Minervini","email":"","orcid":"","institution":"University of Florence, Careggi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Andrea","middleName":"","lastName":"Minervini","suffix":""},{"id":345384731,"identity":"1a6f60f2-cf6c-4f6d-8d89-4ce67e5414e2","order_by":14,"name":"Simone Crivellaro","email":"","orcid":"","institution":"University of Illinois at Chicago","correspondingAuthor":false,"prefix":"","firstName":"Simone","middleName":"","lastName":"Crivellaro","suffix":""}],"badges":[],"createdAt":"2024-07-30 15:38:39","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4829943/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4829943/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":63912855,"identity":"8ff41eba-2366-4569-8dcf-8227315cfe52","added_by":"auto","created_at":"2024-09-03 16:53:14","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":45797,"visible":true,"origin":"","legend":"\u003cp\u003eViolin-plot representing operative time of patients with hostile abdomen treated with Robot Assisted Partial nephrectomy (RAPN)\u003c/p\u003e","description":"","filename":"Figure1OperativetimeofRAPN.png","url":"https://assets-eu.researchsquare.com/files/rs-4829943/v1/1bbd445d976564c8b55379cf.png"},{"id":63914333,"identity":"2ed92afe-d5c9-4d81-9fba-ccf7b3f21a0c","added_by":"auto","created_at":"2024-09-03 17:09:14","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":104829,"visible":true,"origin":"","legend":"\u003cp\u003eProbability of Trifecta achievement according to patients’ complexity\u003c/p\u003e","description":"","filename":"Figure2ProbabilityofTrifectaAchievementrotated.png","url":"https://assets-eu.researchsquare.com/files/rs-4829943/v1/1218958339d905e29598165e.png"},{"id":66574473,"identity":"0a3aaa36-c9d2-402e-94ec-a890f7da67e1","added_by":"auto","created_at":"2024-10-14 12:17:05","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1145692,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4829943/v1/fead3a12-244c-4ee6-88c8-6e2d30e9ebcf.pdf"},{"id":63912854,"identity":"90469334-6b86-4e19-b672-dff828c6b8ab","added_by":"auto","created_at":"2024-09-03 16:53:14","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":18043,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTable1.docx","url":"https://assets-eu.researchsquare.com/files/rs-4829943/v1/c5bafbfb24db0be311101343.docx"},{"id":63912859,"identity":"147c2e17-16f3-4ea2-a415-7069c467835d","added_by":"auto","created_at":"2024-09-03 16:53:14","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":17058,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTable2.docx","url":"https://assets-eu.researchsquare.com/files/rs-4829943/v1/8eb1dedb1caad82185bad82b.docx"},{"id":63912860,"identity":"1c54e5c1-b8ed-4bde-bf6c-bc94dcb6461a","added_by":"auto","created_at":"2024-09-03 16:53:15","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":16024,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTable3.docx","url":"https://assets-eu.researchsquare.com/files/rs-4829943/v1/68d09d6000f7828e46901709.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Retroperitoneal Single Port vs Transperitoneal Multiport Robot Assisted Partial Nephrectomy (RAPN) in Patients with Highly Hostile Abdomens, a tertiary referral center comparative analysis","fulltext":[{"header":"Introduction","content":"\u003cp\u003eDealing with hostile abdomens still represents one of the main surgical challenges in minimally invasive surgery[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Particularly, the worldwide spread of minimally invasive Partial Nephrectomy (PN) for localized T1 renal masses and the continuous advancements in robotic surgery, have widened the indications of Robot Assisted Partial Nephrectomy (RAPN) also in patients with personal history of major abdominal surgery[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. In this setting, the retroperitoneal (RP) surgical access may overcome the limitations of the transperitoneal (TP) one by reducing the risk of adhesions-related intraoperative and perioperative complications as well as shortening the operative time[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Given the central role of surgeons preference in the approach-selection, a clear trend emerged in favor of the adoption of the TP over the RP approach, also due to the wider working space required by the Multi-Port (MP) systems [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. The recent introduction of da Vinci single-port (SP) robotic platform (Intuitive Surgical, Sunnyvale, CA) may shift this paradigm. Indeed, the high flexibility of surgical instruments and the narrow space required for triangulation allow to bring the kidney surgery back to the retroperitoneal space possibly avoiding the above-mentioned adhesion-related issues[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. To date, initial data from both single-center[\u003cspan additionalcitationids=\"CR8\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e] and multi-institutional series[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e] assessed the feasibility of SP-RAPN in unselected patients showing promising results. Nevertheless, evaluating its benefits and harms in highly complex patients still represent an unmet need. As such, we sought to compare retroperitoneal single port RAPN vs transperitoneal multiport RAPN in terms of perioperative and functional outcomes in a cohort of patients with highly hostile abdomens.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy population\u003c/h2\u003e \u003cp\u003eSurgical data of all consecutive patients treated between March 2019 and January 2024 with RP Single-and TP Multi-Port Robot Assisted Partial Nephrectomy at a single center (UIH, Chicago, Illinois, USA) were prospectively included in a self-maintained database and retrospectively gathered. All patients with localized renal masses amenable to partial nephrectomy were included. Demographic, oncologic and perioperative features were collected by a dedicated clinical software (Epic system\u0026reg;) and assessed. The RENAL nephrometry score [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e] was evaluated for each patient basing on the preoperative cross-sectional imaging. Intraoperative and postoperative complications were graded by the Clavien\u0026ndash;Dindo classification system [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] while significant renal function loss was defined in case of ΔeGFR (difference between eGFR at 6-month follow-up and baseline)\u0026thinsp;\u0026gt;\u0026thinsp;25%. The Trifecta achievement was defined accordingly with Kaouk et al.[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e] as the presence of negative pathological surgical margins, absence of perioperative complications and warm ischemia time\u0026thinsp;\u0026lt;\u0026thinsp;25 minutes.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eHostile Abdomen\u003c/h2\u003e \u003cp\u003eThe presence of \u0026ldquo;hostile abdomen\u0026rdquo; was defined as the personal history of at least one major transperitoneal abdominal surgery (a comprehensive report is provided in Supplementary Table\u0026nbsp;1). Previous surgery was also compared according to its proximity to the site of the partial nephrectomy in two categories (upper contralateral/lower abdominal quadrant or minimally invasive, upper ipsilateral abdominal quadrant or middle line). Only patients with \u0026ldquo;hostile abdomen\u0026rdquo; were included in the analysis. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The present research was performed after local ethical commitment approval IRB 20201428. Basing on surgical approach, patients were stratified in two groups (Retroperitoneal SP-RAPN vs Transperitoneal MP-RAPN).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eSurgical technique\u003c/h2\u003e \u003cp\u003eAll transperitoneal MP-RAPN cases were performed at our institution by two surgeons with extensive experience using the standard multiport da Vinci Xi system according to the previously described standard technique [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. All retroperitoneal SP-RAPN procedures were performed with da Intuitive daVinci SP system\u0026reg; and surgical approach was defined according to the surgeon's preference as previously reported (full flank standard approach vs Low Anterior Access (LAA)[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eThe Statistical analyses were conducted following established guidelines [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Descriptive statistics were obtained reporting medians (and interquartile range, IQR) for continuous variables, while frequencies and proportions were used for categorical variables. After testing the normality of variables\u0026rsquo; distribution (by the Kolmogorov-Smirnov test), continuous variables were compared by the Mann-Whitney test. We statistically analyzed baseline characteristics and peri- and post-operative outcomes, comparing the TP MP- and the RP SP- RAPN. Multivariable logistic regression analysis was used to test the probability of the Trifecta achievement adjusting for surgical approach, ASA score, CCI and BMI. All statistical analyses were performed using R software (version 4.3.2).\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003eOverall, clinical and surgical data of 247 consecutive patients treated with RAPN at our institution were prospectively collected and retrospectively analyzed. Of these, 87 (35.2%) were treated with retroperitoneal SP-RAPN while 113 (45.7%) underwent transperitoneal MP-RAPN. The presence of complex abdomen was recorded in 28 (32.2%) and 43 (38.1%) cases in the RP SP-RAPN and TP MP-RAPN, respectively. A detailed description of patient previous abdominal surgery is represented in Supplementary Table\u0026nbsp;1. In terms of baseline features no significant differences were recorded, median age at surgery was 57 (IQR 44\u0026ndash;68) and 58 (IQR 48\u0026ndash;65) years while median BMI was 30.12 (IQR 26.1\u0026ndash;36.6) and 31.30 (IQR 25.1\u0026ndash;38.3) kg/m2 in the RP SP-RAPN and TP MP-RAPN, respectively (p\u0026thinsp;=\u0026thinsp;0.8, p\u0026thinsp;=\u0026thinsp;0.18). Previous surgery proximity to the site of partial nephrectomy was found comparable among groups (p\u0026thinsp;=\u0026thinsp;0.21). Although preoperative hypertension was found higher among the SP group (p\u0026thinsp;=\u0026thinsp;0.04), no differences emerged in overall patient complexity with a median CCI score of 3 (IQR 2\u0026ndash;4) and 3 (IQR 2\u0026ndash;5) in the RP SP-RAPN and TP MP-RAPN, respectively (p\u0026thinsp;=\u0026thinsp;0.7) Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. As regards tumor features, no significant differences were recoded between groups in terms median RENAL Nephrometry Score (8 [IQR 6\u0026ndash;9] vs 7 [IQR 5\u0026ndash;8] p\u0026thinsp;=\u0026thinsp;0.2) as well as clinical T stage (p\u0026thinsp;=\u0026thinsp;0.9) while a slightly higher although not significant rate of posterior tumors was recorded in the SP group (p\u0026thinsp;=\u0026thinsp;0.06). Considering intraoperative outcomes, RP SP-RAPN showed a significantly lower operative time (171 min [IQR 104\u0026ndash;238] vs 235 min [IQR 160\u0026ndash;302)], p\u0026thinsp;=\u0026thinsp;0.02) and estimated blood loss (70 cc [IQR 40\u0026ndash;170)] vs 100 cc [IQR 60\u0026ndash;200], p\u0026thinsp;=\u0026thinsp;0.04), Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. Open conversion occurred in the 9.3% of patients treated with TP MP-RAPN while no cases were recorded in the RP SP-RAPN group (p\u0026thinsp;=\u0026thinsp;0.001). In term of hilar clamping no significant differences were found among groups with a slightly higher rate of off-clamp procedures in the MP group (p\u0026thinsp;=\u0026thinsp;0.07), Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e. As regards postoperative outcomes, a significantly lower rate of major postoperative complications was found in the RP SP-RAPN group as compared to the TP MP-RAPN (7.1% vs 16.3%, p\u0026thinsp;=\u0026thinsp;0.03), as well as a significantly lower rate of 90-days readmission (7.1% vs 14.1%, p\u0026thinsp;=\u0026thinsp;0.04) Supplementary Table\u0026nbsp;2. In terms of mid-term surgical and functional outcomes, after a median follow up of 16 months (IQR 6\u0026ndash;24) no differences were recorded in terms of significant renal function loss (p\u0026thinsp;=\u0026thinsp;0.9). Adjusting for age, BMI and CCI, RP SP-RAPN was confirmed as independent predictor of Trifecta achievement (OR 1.62 CI 1.18\u0026ndash;2.35 p\u0026thinsp;=\u0026thinsp;0.01), Supplementary Table\u0026nbsp;3.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eComparison of the preoperative characteristics of patients with hostile abdomen treated with transperitoneal multiport or retroperitoneal single port RAPN\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003eCharacteristic\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eOverall, N\u0026thinsp;=\u0026thinsp;71\u003csup\u003e\u003cem\u003e1\u003c/em\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMultiport Transperitoneal RAPN, N\u0026thinsp;=\u0026thinsp;43\u003csup\u003e\u003cem\u003e1\u003c/em\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eSingle Port Retroperitoneal RAPN, N\u0026thinsp;=\u0026thinsp;28\u003csup\u003e\u003cem\u003e1\u003c/em\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003ep-value\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAge at Surgery, median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e58 (48\u0026ndash;65)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e58 (48\u0026ndash;65)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e57 (44\u0026ndash;68)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eGender (male), n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e47 (66.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e28 (65.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e19 (67.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.08\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBMI (kg/m2), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e30.8 (25.6\u0026ndash;37.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e31.3 (25.1\u0026ndash;38.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e30.1 (26.1\u0026ndash;36.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.18\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eRace, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.06\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eWhite\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e18 (25.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e11 (25.6%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7 (25)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eBlack\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e18 (25.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10 (23.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e8 (28.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eHispanic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e15 (21.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e9 (20.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6 (21.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eChinese\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9 (12.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e5 (11.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4 (14.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eSouth-Asia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11 (15.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e8 (18.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3 (10.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCCI, median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4 (3\u0026ndash;5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4 (3\u0026ndash;5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4 (3\u0026ndash;5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eASA, median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3 (2\u0026ndash;4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3 (2\u0026ndash;4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3 (2\u0026ndash;5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHypertension, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e43 (61%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e22 (51%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e21 (75%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e0.04\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDiabetes, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e24 (34%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e14 (33%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e10 (36%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAntiplatelet or anticoagulant therapy, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e15 (21%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e9 (20.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6 (21%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;0.9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePrevious surgery location, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eUpper contralateral, lower abdominal quadrants or minimally invasive, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e45 (63.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e28 (65.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e17 (60.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eUpper ipsilateral abdominal quadrant or middle line, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e26 (36.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e15 (34.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e11 (39.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.11\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePreoperative Hb (g/dL), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e12.40 (9.7\u0026ndash;15.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e12.30 (10.1\u0026ndash;15.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e12.80 (9.2\u0026ndash;16.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePreoperative serum creatinine (mg/dL), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.83 (0.71\u0026ndash;1.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.71 (0.65\u0026ndash;1.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.88 (0.67\u0026ndash;1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePreoperative eGFR (mL/min/1.73m2), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e87 (51\u0026ndash;90)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e84 (49\u0026ndash;86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e88 (58\u0026ndash;90)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eClinical tumor size (mm), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.50 (1.9\u0026ndash;3.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.55 (1.7\u0026ndash;3.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2.50 (1.5\u0026ndash;3.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eClinical T stage, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ecT1a\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e61 (85.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e36 (83.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e25 (89.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ecT1b\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10 (14.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7 (16.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3 (10.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eRenal Nephrometry score, median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7 (5\u0026ndash;9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7 (5\u0026ndash;8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e8 (6\u0026ndash;9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePosterior lesions, n(%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e26 (36.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e15 (34.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e11 (39.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.06\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e \u003cp\u003e\u003csup\u003e\u003cb\u003e1\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eMedian (IQR); n / N (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e \u003cp\u003e\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eWilcoxon rank sum test; Fisher\u0026rsquo;s exact test; Pearson\u0026rsquo;s Chi-squared test\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePerioperative and pathological outcomes of patients with hostile abdomen treated with transperitoneal multiport or retroperitoneal single port RAPN\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eCharacteristic\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eOverall, N\u0026thinsp;=\u0026thinsp;71\u003csup\u003e\u003cem\u003e1\u003c/em\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMultiport Transperitoneal RAPN, N\u0026thinsp;=\u0026thinsp;43\u003csup\u003e\u003cem\u003e1\u003c/em\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSingle Port Retroperitoneal RAPN, N\u0026thinsp;=\u0026thinsp;28\u003csup\u003e\u003cem\u003e1\u003c/em\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003ep-value\u003csup\u003e\u003cem\u003e2\u003c/em\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eOperative time (min), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e197 (120\u0026ndash;280)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e235 (160\u0026ndash;302)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e171 (104\u0026ndash;238)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.019\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEBL (cc), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e80 (50\u0026ndash;130)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100 (60\u0026ndash;200)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e70 (40\u0026ndash;170)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.04\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eClampless procedures, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8 (11.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5 (11.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3 (10.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.11\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eIschemia Time (min), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18 (14\u0026ndash;22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e18 (14\u0026ndash;21)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e19 (16\u0026ndash;23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.09\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eOpen conversion, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4 (5.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4 (9.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTransfusion rate, n(%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (9.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5 (11.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (7.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.08\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHb level at discharge (g/dL), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10.7 (9.7\u0026ndash;15.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10.4 (9.2\u0026ndash;13.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e11.1 (9.9\u0026ndash;14.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSerum creatinine level at discharge (mg/dL), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.12 (0.71\u0026ndash;1.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.10 (0.87\u0026ndash;1.32)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.18 (0.91\u0026ndash;1.43)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eeGFR level at discharge (mL/min/1.73m2), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e69 (51\u0026ndash;90)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e71 (46\u0026ndash;84)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e67(43\u0026ndash;82)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLength of Hospital stay (LOS), median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (0\u0026ndash;3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3 (2\u0026ndash;4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0 (0\u0026ndash;1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eOpioid use on 0 or 1 PO Day, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e53 (74.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e33 (76.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10 (35.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNarcotic use one week after surgery, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12 (16.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9 (20.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3 (10.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.03\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEarly postoperative complications CD\u003c/b\u003e\u0026thinsp;\u003cspan type=\"BoldUnderline\" class=\"BoldUnderline\" name=\"Emphasis\"\u003e\u0026ge;\u003c/span\u003e\u0026thinsp;\u003cb\u003e3a, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9 (12.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7 (16.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (7.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.03\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003e90-days readmission rate, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16 (23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6 (14.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (7.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.04\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePositive Surgical Margin, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (9.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4 (13.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (7.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePathological T stage, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e63 (88.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e40 (93.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e23 (82.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003epT1a\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e52 (82.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e33 (75.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e19 (82.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003epT1b\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11 (15.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7 (17.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4 (17.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSignificant renal function loss at last follow up\u003c/b\u003e \u003csup\u003e\u003cb\u003e3\u003c/b\u003e\u003c/sup\u003e, \u003cb\u003en(%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32 (45)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19 (44)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e13 (46)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eFollow-up, median (IQR)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18 (12\u0026ndash;24)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e20 (14\u0026ndash;26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e16 (12\u0026ndash;20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.06\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003e\u003csup\u003e\u003cb\u003e1\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eMedian (IQR); n / N (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e \u003cp\u003e\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eWilcoxon rank sum test; Fisher\u0026rsquo;s exact test; Pearson\u0026rsquo;s Chi-squared test\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eDuring the last decades, minimally invasive nephron sparing surgery further widened its broadens confirming valuable outcomes in managing more complex patient and tumors settings [\u003cspan additionalcitationids=\"CR18\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Nevertheless, the presence of intraperitoneal adhesions due to previous major abdominal surgery still represent a non-negligible surgical challenge possibly jeopardizing perioperative safety and prolonging the operative time [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Notwithstanding the theoretical advantages provided by the RP approach in these patients, the confined space of work and the less familiar anatomical landmarks still burden on its adoption across the urological community [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. This factor is also driven by the inherent limitations of multiport robotic systems that have led to a progressive shift of kidney surgery towards the transperitoneal approach [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. In this scenario, several preliminary series evaluating SP-RAPN outlined a trend reversal with a growing body of surgeons performing RP approach with both full flank and supine patient positioning [\u003cspan additionalcitationids=\"CR8 CR9\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. Nevertheless, the potential benefits of RP SP-RAPN in the complex abdomen patient-setting are still undetermined.\u003c/p\u003e \u003cp\u003eTo the best of our knowledge, this represents the first series focused on patients with hostile abdomens comparing perioperative and functional outcomes of transperitoneal MP- vs retroperitoneal SP- RAPN.\u003c/p\u003e \u003cp\u003eFirst key finding of our research is that RP SP-RAPN significantly reduced the rates of perioperative complications as compared to the transperitoneal MP group, thus increasing the surgical safety in patients with hostile abdomens. This result might be explained by the reduced tissue dissection and the avoidance of adhesiolysis that is usually performed laparoscopically in the first steps of MP procedures, often representing in this setting a technically demanding surgery [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Consistently to our results, a large multi-institutional matched series assessing both robot-assisted and laparoscopic TP vs RP PN outlined a significant higher major-complications rate in case of transperitoneal procedures [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Conversely, a recent comparative series assessing trans- versus retroperitoneal MP RAPN pointed out no differences in terms of perioperative complications across study cohorts [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. To date, previous surgery was reported in few than the 20% of patients and no data regarding the kind of surgery were provided, possibly lowering the statistical burden of extended adhesiolysis in the perioperative outcome assessment. Although a recent meta-analysis by Carbonara et. al[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e] found a higher overall complications rate considering both matched and unmatched series in the TP vs RP approach, no differences were found in terms of CD\u0026thinsp;\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e\u0026ge;\u003c/span\u003e\u0026thinsp;3a complications. Beyond first appearance, our findings are possibly in line with these reports non-focused on complex abdomens. Indeed, our highly surgically complex study population might have enhanced the pre-existing differences between approaches, thus bringing to the surface different safety profiles when it deals with previous major surgery. In this light, in our series open conversion rate was significantly higher in the transperitoneal group occurring in up to the 9% of cases while no conversions were recorded in the RP SP group, confirming its higher feasibility in these patients.\u003c/p\u003e \u003cp\u003eSecondly, as compared to the transperitoneal group RP SP-RAPN significantly reduced EBL, operative time and LOS also improving pain management and opioid administration. The convergence of these factors makes a strong argument in favor of both SP and RP adoption in minimizing the surgical impact on complex patients. From a perioperative standpoint, the advantages of the retroperitoneal approach have been widely discussed across current literature with several series identifying the surgeon preference as the main limiting factor in its adoption [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. In this scenario, the introduction of SP surgical system may play a pivotal role making easier and more feasible dealing with the retroperitoneal space also in challenging cases [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. On top of that, given the median BMI up to 30 kg/m2 of our study population, the presence of abundant perinephric fat did not affect the feasibility of the SP RP approach, with reported perioperative outcomes consistent with current literature [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThird, assessing the Trifecta achievement accordingly with Kaouk et al.[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e] as a surrogate of surgical and oncological safety, the RP SP group showed significative higher values as compared to the MP procedures (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). Acknowledging the burden of perioperative complications in this statistical significance, is interesting to notice that PSM rate was comparable among groups even in case of anterior lesions. With the advent of minimally invasive surgery, the retroperitoneal approach was always preferred by surgeons for managing posterior renal masses, while anterior lesions were typically managed transperitoneally[\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. Conversely, in our study a relatively high value of anterior lesion was found in the RP group. This factor is possibly driven by the high rate of SP-RAPN performed with supine LAA (76%), thus confirming its versatility and surgical benefits across a wide variety of procedures on the upper urinary tract and regardless to the tumor location [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThis study is not devoid from limitations. Firstly, the retrospective nature of the analysis in conjunction with the single-center and multiple-surgeon setting may have introduced non-negligible biases. Secondly, the reproducibility of the reported results may have been reduced by the small sample size. To date, to the best of our knowledge this constitutes the larger series focused on perioperative outcomes of SP PN in patients with complex abdomens through current literature. Finally, the density of peritoneal adhesions was not determined intraoperatively due to the retrospective study design. Nevertheless, only patients with high risk of adhesions formation due to previous major procedures were included, possibly reducing the aforementioned flaws [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e], [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. Concluding, further muti-center series with longer follow up and larger sample size are still warranted to assess our preliminary outcomes.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eIn a cohort of patients with highly hostile abdomens treated with RAPN, single port retroperitoneal approach confirmed valuable perioperative outcomes reducing the perioperative complication rate as compared to the multiport transperitoneal approach. Additionally, in this patient setting retroperitoneal single port access minimized the overall surgical impact in patients by improving EBL, operative time, LOS and pain management. Further multicenter series with longer follow up assessment are still warranted to evaluate our preliminary results.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNone.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNo funding was received in each step of this research.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of interest/Competing interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial interests:\u003c/strong\u003e The authors declare they have no financial interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNon-financial interests:\u0026nbsp;\u003c/strong\u003eNone.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors contributions:\u003c/strong\u003e Conceptualization Luca Lambertini, Simone Crivellaro; Data curation Gabriele Bignante, Francesco Lasorsa, Matteo Pacini, Francesca Valastro; Formal analysis; Luca Lambertini, Fabrizio Di Maida, Andrea Mari, Investigation Donato Cannoletta, Greta Pettenuzzo; Methodology Ruben Sauer, Juan Ramon Torres Anguiano; Supervision Alessandro Zucchi; Validation Andrea Minervini; Writing - original draft Luca lambertini; and Writing - review \u0026amp; editing Luca Lambertini, Simone Crivellaro.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability Statement:\u003c/strong\u003e The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics Committee Approval:\u0026nbsp;\u003c/strong\u003eAll procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The present research was performed after local ethical commitment approval (University of Illinois in Chicago, 26\u003csup\u003eth\u003c/sup\u003e June 2016) IRB 20201428.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent to participate:\u003c/strong\u003e Informed consent was obtained from all individual participants included in the study. The authors affirm that human research participants provided informed consent for publication of the collected data.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003ePetros FG et al (Aug. 2011) Robotic partial nephrectomy in the setting of prior abdominal surgery. BJU Int 108(3):413\u0026ndash;419. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1464-410X.2010.09803.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1464-410X.2010.09803.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZargar H et al (2015) Dec., Robot-assisted laparoscopic partial nephrectomy in patients with previous abdominal surgery: single center experience., \u003cem\u003eInt J Med Robot\u003c/em\u003e, vol. 11, no. 4, pp. 389\u0026ndash;394, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/rcs.1633\u003c/span\u003e\u003cspan address=\"10.1002/rcs.1633\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eArora S et al (Oct. 2018) Retroperitoneal vs Transperitoneal Robot-assisted Partial Nephrectomy: Comparison in a Multi-institutional Setting. Urology 120:131\u0026ndash;137. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.urology.2018.06.026\u003c/span\u003e\u003cspan address=\"10.1016/j.urology.2018.06.026\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCarbonara U et al (Jun. 2022) Retroperitoneal Robot-assisted Partial Nephrectomy: A Systematic Review and Pooled Analysis of Comparative Outcomes. Eur Urol Open Sci 40:27\u0026ndash;37. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.euros.2022.03.015\u003c/span\u003e\u003cspan address=\"10.1016/j.euros.2022.03.015\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFu J, Ye S, Ye H (Dec. 2015) Retroperitoneal Versus Transperitoneal Laparoscopic Partial Nephrectomy: A Systematic Review and Meta-analysis. Chin Med Sci J 30(4):239\u0026ndash;244. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s1001-9294(16)30007-4\u003c/span\u003e\u003cspan address=\"10.1016/s1001-9294(16)30007-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePellegrino AA, Chen G, Morgantini L, Calvo RS, Crivellaro S (2023) Simplifying Retroperitoneal Robotic Single-port Surgery: Novel Supine Anterior Retroperitoneal Access., \u003cem\u003eEur Urol\u003c/em\u003e, vol. 84, no. 2, pp. 223\u0026ndash;228, Aug. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.eururo.2023.05.006\u003c/span\u003e\u003cspan address=\"10.1016/j.eururo.2023.05.006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGlaser ZA et al (2022) Jun., Single- versus multi-port robotic partial nephrectomy: a comparative analysis of perioperative outcomes and analgesic requirements., \u003cem\u003eJ Robot Surg\u003c/em\u003e, vol. 16, no. 3, pp. 695\u0026ndash;703, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11701-021-01271-y\u003c/span\u003e\u003cspan address=\"10.1007/s11701-021-01271-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHarrison R et al (Feb. 2023) Single-port versus multiport partial nephrectomy: a propensity-score-matched comparison of perioperative and short-term outcomes. J Robot Surg 17(1):223\u0026ndash;231. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11701-022-01415-8\u003c/span\u003e\u003cspan address=\"10.1007/s11701-022-01415-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLicari LC et al (Mar. 2024) Single-port vs multi-port robot-assisted partial nephrectomy: A single center propensity score-matched analysis. Eur J Surg Oncol 50(3):108011. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ejso.2024.108011\u003c/span\u003e\u003cspan address=\"10.1016/j.ejso.2024.108011\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOkhawere KE et al (2022) Dec., A Propensity-Matched Comparison of the Perioperative Outcomes Between Single-Port and Multi-Port Robotic Assisted Partial Nephrectomy: A Report from the Single Port Advanced Research Consortium (SPARC)., \u003cem\u003eJ Endourol\u003c/em\u003e, vol. 36, no. 12, pp. 1526\u0026ndash;1531, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1089/end.2022.0115\u003c/span\u003e\u003cspan address=\"10.1089/end.2022.0115\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth., \u003cem\u003eJ Urol\u003c/em\u003e, vol. 182, no. 3, pp. 844\u0026ndash;853, Sep. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.juro.2009.05.035\u003c/span\u003e\u003cspan address=\"10.1016/j.juro.2009.05.035\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClavien PA et al (Aug. 2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187\u0026ndash;196. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/SLA.0b013e3181b13ca2\u003c/span\u003e\u003cspan address=\"10.1097/SLA.0b013e3181b13ca2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKhalifeh A et al (Apr. 2013) Comparative outcomes and assessment of trifecta in 500 robotic and laparoscopic partial nephrectomy cases: a single surgeon experience. J Urol 189(4):1236\u0026ndash;1242. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.juro.2012.10.021\u003c/span\u003e\u003cspan address=\"10.1016/j.juro.2012.10.021\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLarcher A et al (2019) Feb., The Learning Curve for Robot-assisted Partial Nephrectomy: Impact of Surgical Experience on Perioperative Outcomes., \u003cem\u003eSwitzerland\u003c/em\u003e. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.eururo.2018.08.042\u003c/span\u003e\u003cspan address=\"10.1016/j.eururo.2018.08.042\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRohi A, Olofsson MET, Jakobsson JG (2022) Ambulatory anesthesia and discharge: an update around guidelines and trends., \u003cem\u003eCurr Opin Anaesthesiol\u003c/em\u003e, vol. 35, no. 6, pp. 691\u0026ndash;697, Dec. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/ACO.0000000000001194\u003c/span\u003e\u003cspan address=\"10.1097/ACO.0000000000001194\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAssel M et al (2019) Mar., Guidelines for Reporting of Statistics for Clinical Research in Urology., \u003cem\u003eSwitzerland\u003c/em\u003e. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.eururo.2018.12.014\u003c/span\u003e\u003cspan address=\"10.1016/j.eururo.2018.12.014\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDi Maida F et al (2022) Surgical Management of Synchronous, Bilateral Renal Masses: A 1-decade Referral Center Experience, \u003cem\u003eEur Urol Focus\u003c/em\u003e, no. xxxx, pp. 1\u0026ndash;9, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.euf.2022.01.010\u003c/span\u003e\u003cspan address=\"10.1016/j.euf.2022.01.010\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDi Maida F et al (2023) Nov., Redo Partial Nephrectomy for Local Recurrence After Previous Nephron-sparing Surgery. Surgical Insights and Oncologic Results from a High-volume Robotic Center., \u003cem\u003eEur Urol Open Sci\u003c/em\u003e, vol. 57, pp. 84\u0026ndash;90, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.euros.2023.09.007\u003c/span\u003e\u003cspan address=\"10.1016/j.euros.2023.09.007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLambertini L et al (Apr. 2024) Minimally invasive transperitoneal partial versus radical nephrectomy in obese patients: perioperative and long-term functional outcomes from a large perspective contemporary series (RECORd2 project). Minerva Urol Nephrol 76(2):185\u0026ndash;194. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.23736/S2724-6051.24.05692-1\u003c/span\u003e\u003cspan address=\"10.23736/S2724-6051.24.05692-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBourgi A, Ayoub E, Merhej S, Souky J, Roupret M, Bruy\u0026egrave;re F (2023) A comparison of perioperative outcomes of transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a systematic review., \u003cem\u003eJ Robot Surg\u003c/em\u003e, vol. 17, no. 6, pp. 2563\u0026ndash;2574, Dec. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11701-023-01685-w\u003c/span\u003e\u003cspan address=\"10.1007/s11701-023-01685-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBertolo R et al (Feb. 2024) Postoperative outcomes of transperitoneal versus retroperitoneal robotic partial nephrectomy: a propensity-score matched comparison focused on patient mobilization, return to bowel function, and pain. J Robot Surg 18(1):96. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11701-024-01860-7\u003c/span\u003e\u003cspan address=\"10.1007/s11701-024-01860-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbaza R, Gerhard RS, Martinez O (May 2020) Feasibility of adopting retroperitoneal robotic partial nephrectomy after extensive transperitoneal experience. World J Urol 38(5):1087\u0026ndash;1092. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00345-019-02935-z\u003c/span\u003e\u003cspan address=\"10.1007/s00345-019-02935-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePorpiglia F et al (2021) Aug., Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (The RECORD 2 Project)., \u003cem\u003eSurg Endosc\u003c/em\u003e, vol. 35, no. 8, pp. 4295\u0026ndash;4304, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00464-020-07919-4\u003c/span\u003e\u003cspan address=\"10.1007/s00464-020-07919-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePorpiglia F et al (2021) Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (The RECORD 2 Project). Surg Endosc 35(8):4295\u0026ndash;4304. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00464-020-07919-4\u003c/span\u003e\u003cspan address=\"10.1007/s00464-020-07919-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePalacios AR, Morgantini L, Trippel R, Crivellaro S, Abern MR (2022) Comparison of Perioperative Outcomes Between Retroperitoneal Single-Port and Multiport Robot-Assisted Partial Nephrectomies., \u003cem\u003eJ Endourol\u003c/em\u003e, vol. 36, no. 12, pp. 1545\u0026ndash;1550, Dec. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1089/end.2022.0346\u003c/span\u003e\u003cspan address=\"10.1089/end.2022.0346\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMalkoc E et al (2017) Feb., Robot-assisted approach improves surgical outcomes in obese patients undergoing partial nephrectomy., \u003cem\u003eBJU Int\u003c/em\u003e, vol. 119, no. 2, pp. 283\u0026ndash;288, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/bju.13675\u003c/span\u003e\u003cspan address=\"10.1111/bju.13675\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRich JM et al (2023) Nov., Transperitoneal Versus Retroperitoneal Single-port Robotic-assisted Partial Nephrectomy: An Analysis from the Single Port Advanced Research Consortium., \u003cem\u003eEur Urol Focus\u003c/em\u003e, vol. 9, no. 6, pp. 1059\u0026ndash;1064, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.euf.2023.06.004\u003c/span\u003e\u003cspan address=\"10.1016/j.euf.2023.06.004\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRazdan S et al (May 2024) Comparison of lateral flank approach and low anterior access for single port (SP) retroperitoneal partial nephrectomy: an analysis from the single port advanced research consortium (SPARC). J Robot Surg 18(1):216. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11701-024-01969-9\u003c/span\u003e\u003cspan address=\"10.1007/s11701-024-01969-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiakakos T, Thomakos N, Fine PM, Dervenis C, Young RL (2001) Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg 18(4):260\u0026ndash;273. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1159/000050149\u003c/span\u003e\u003cspan address=\"10.1159/000050149\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCeyhan E et al (2021) Pathology associated with adherent perirenal fat and its clinical effect. Int J Clin Pract 75(10):1\u0026ndash;7. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ijcp.14518\u003c/span\u003e\u003cspan address=\"10.1111/ijcp.14518\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Previous surgery, Robotics, Nephrectomy, Renal cancer, Complications","lastPublishedDoi":"10.21203/rs.3.rs-4829943/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4829943/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003ePurpose\u003c/h2\u003e \u003cp\u003eTo explore perioperative and functional outcomes in a cohort of patients with highly hostile abdomens treated with retroperitoneal single port vs transperitoneal multiport robot assisted partial nephrectomy.\u003c/p\u003e\u003ch2\u003eMaterials and Methods\u003c/h2\u003e \u003cp\u003eClinical and surgical data of all consecutive patients treated with Transperitoneal Multiport and Retroperitoneal Single-Port Robot Assisted Partial Nephrectomy between March 2019 and January 2024 were prospectively collected and retrospectively analyzed. The presence of \u0026ldquo;hostile abdomen\u0026rdquo; was defined as personal history of at least one major abdominal surgery. Multivariable logistic regression analysis was used to assess independent predictors of Trifecta achievement.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eOverall, clinical and surgical data of 247 consecutive patients were prospectively collected, of these 71 met the inclusions criteria and were retrospectively analyzed. No differences emerged in baseline features. Previous surgery proximity to the site of partial nephrectomy was found comparable among groups (p\u0026thinsp;=\u0026thinsp;0.21). Retroperitoneal single port group showed a significantly lower operative time (171 vs 235 min, p\u0026thinsp;=\u0026thinsp;0.02) and estimated blood loss (70 vs 100 cc, p\u0026thinsp;=\u0026thinsp;0.04) while open conversion was significantly higher (9.3%) in case of multiport treatment (p\u0026thinsp;=\u0026thinsp;0.001). A significative lower rate of major postoperative complications (7.1 vs 16.3%, p\u0026thinsp;=\u0026thinsp;0.03) as well as 90-days readmissions (p\u0026thinsp;=\u0026thinsp;0.04) was found in case of single port retroperitoneal procedures. Adjusting for age, BMI and CCI, retroperitoneal single port approach was confirmed as independent predictor of Trifecta achievement (OR 1.62 CI 1.18\u0026ndash;2.35 p\u0026thinsp;=\u0026thinsp;0.01).\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eSingle port retroperitoneal approach confirmed valuable perioperative outcomes reducing the major complication rate and minimizing the overall surgical impact on patients as compared to the multiport transperitoneal group.\u003c/p\u003e","manuscriptTitle":"Retroperitoneal Single Port vs Transperitoneal Multiport Robot Assisted Partial Nephrectomy (RAPN) in Patients with Highly Hostile Abdomens, a tertiary referral center comparative analysis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-09-03 16:53:09","doi":"10.21203/rs.3.rs-4829943/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"7cd2c015-38e0-4598-a423-eb1b95771804","owner":[],"postedDate":"September 3rd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-10-14T12:08:55+00:00","versionOfRecord":[],"versionCreatedAt":"2024-09-03 16:53:09","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4829943","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4829943","identity":"rs-4829943","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}